Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All DataMeds AI, Inc. filings on SEC EDGAR ↗
DataMEDS AI, Inc. entered into an at-the-market (ATM) sales agreement with Dawson James Securities, Inc. to establish an offering program for its common stock. The company may sell shares from time to time at prevailing market prices, though it is not obligated to make any sales. The Sales Agent will receive a fixed commission of 3.0% of the gross proceeds from any shares sold.
DataMeds AI M&A Deal with EOS Technology Holdings, Inc.
DataMEDS AI entered into a second amended and restated non-binding letter of intent to acquire intellectual property assets from EOS and Scilex Holding Company, and a controlling interest in Tollo Health (d/b/a Health Lives Here). The transaction involves an exchange of membership interests and the issuance of common stock that will result in the counterparties owning approximately 89.5% of the company's common stock on a fully diluted basis.
DataMeds AI, Inc. received formal notification from Nasdaq on October 19, 2026, confirming that the company has regained compliance with the $2.5 million minimum stockholders' equity requirement for continued listing. The company had previously been in deficiency since April 2026 and had also recently regained compliance with the minimum bid-price requirement in June 2026.
DataMeds AI Licensing Deal with REBOOT Health AI, Inc. Worth $2M
DataMeds AI, Inc. entered into an exclusive intellectual property license agreement with REBOOT Health AI to use its AI platform for DataMeds' GLP-1 weight management business. As consideration, DataMeds will issue 666,667 shares of common stock with a guaranteed minimum value of $2 million after 180 days, plus a revenue-sharing arrangement. The company also disclosed it remains below Nasdaq's minimum stockholders' equity requirement for continued listing.